The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.
Michael A. Nalesnik(University of Pittsburgh), Joseph Locker(University of Pittsburgh), Ronald Jaffe(Stanford University), K. A. Porter(University of Pittsburgh), L Makowka, A J Demetris, M. Ho(University Health Network), Thomas E. Starzl(University of Pittsburgh Medical Center), Judith Burnham
PubMed
October 1, 1988
Cited by 703
Related Papers
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k
REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY
|The Lancet|1984|1.3k
Production of α1,3-Galactosyltransferase-Deficient Pigs
|Science|2003|1.1k
Evolution of Liver Transplantation
|Hepatology|1982|887
Clinical Pharmacokinetics of Tacrolimus
|Clinical Pharmacokinetics|1995|802